Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

SCHWERPUNKT: AKUTE UND CHRONISCHE LEUKÄMIEN

Chronische lymphatische Leukämie (S. 18–24)
Christof Schneider, Daniela Steinbrecher, Stephan Stilgenbauer

  1. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie zur Diagnostik, Therapie und Nachsorge für Patienten mit einer chronischen lymphatischen Leukämie (CLL); 2018 [cited 2018 Aug 21]. Available from: URL: www.leitlinienprogramm-onkologie.de/leitlinien/chronische-lymphatische-leukaemie-cll/
  2. Goldin LR, Björkholm M, Kristinsson SY, Turesson I, Landgren O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin’s lymphomas among relatives of patients with chronic lymphocytic leukemia. haematologica 2009: haematol 2008.003632
  3. Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia. ASH Education Program Book 2015; 2015(1): 368–77
  4. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood 2018: blood-2017-09-806398
  5. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015; 26(suppl_5): v78–v84
  6. Stilgenbauer S. Chronische lymphatische Leukämie (CLL): Fortschritte im Management: Thieme; 2016
  7.  Wendtner C-M, Dreger P, Gregor M, Greil R, Knauf WU, Pritzkuleit R et al. Chronische Lymphatische Leukämie (CLL). Leitlinie; 2014 [cited August 2018]. Available from: URL: www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@view/html/index.html
  8. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526(7574): 525–30
  9. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475(7354): 101
  10. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature medicine 2013; 19(2): 202
  11. Gribben JG. How and when I do allogeneic transplant in CLL. Blood 2018: blood-2018-01-785998
  12. Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies. Blood 2018: blood-2018-01-826008
  13. Hallek M, Fischer K, Fingerle-Rowson G, Am Fink, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. The Lancet 2010; 376(9747): 1164–74
  14. Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. The lancet oncology 2016; 17(7): 928–42
  15. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New England Journal of Medicine 2014; 370(12): 1101–10
  16. Goede V, Fischer K, Dyer MJ, Müller L, Smolej L, Di Bernardo MC et al. overall survival benefit of Obinutuzumab over Rituximab when combined with Chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study; 2018 [cited 2018 Aug 20]
  17. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England Journal of Medicine 2015; 373(25): 2425–37
  18. Michallet A-S, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label MABLE study. haematologica 2018: haematol 2017.170480
  19. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): A phase 2, open-label, multicentre study. The lancet oncology 2016; 17(10): 1409–18
  20. Daugaard G, Gundgaard MG, Mortensen MS, Agerbaek M, Holm NV, Rorth M, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 2014; 32(34): 3817–23
  21. Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of clinical oncology 2018: JCO 2017.76. 6840
  22. Seymour JF, Kipps TJ, Eichhorst BF, Hillmen P, D'Rozario JM, Assouline S et al. Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia-results from pre-planned interim analysis of the randomized phase 3 murano study: Am Soc Hematology; 2017
  23. Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 2018: blood-2018-05-853564
  24. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England Journal of Medicine 2014; 370(11): 997–1007